Comparison of Two Creatinine-Based Equations for Predicting Decline in Renal Function in Type 2 Diabetic Patients with Nephropathy in a Korean Population
Table 2
Crude and adjusted Cox proportional hazard ratios for doubling of baseline serum creatinine level in 707 type 2 diabetic patients with nephropathy stratified by CKD stage according to each equation.
HR
95% CI
HR
95% CI
CKDMDRD
<0.0001
CKDCKD-EPI
<0.0001
Stage 1: ≥90
1
Reference
Stage 1: ≥90
1
Reference
Stage 2: 60–89
1.54
0.72–3.32
0.2679
Stage 2: 60–89
1.90
0.97–3.73
0.0630
Stage 3a: 45–59
1.79
0.79–4.07
0.1658
Stage 3a: 45–59
2.18
1.04–4.55
0.0383
Stage 3b: 30–44
4.11
1.92–8.82
0.0003
Stage 3b: 30–44
4.31
2.19–8.48
<0.0001
Stage 4: 15–29
4.40
2.04–9.49
0.0002
Stage 4: 15–29
5.08
2.56–10.08
<0.0001
Stage 5: <15
6.64
2.66–16.61
<0.0001
Stage 5: <15
8.09
3.65–17.95
<0.0001
Adjusted model 1
<0.0001
Adjusted model 1
<0.0001
Stage 1: ≥90
1
Reference
Stage 1: ≥90
1
Reference
Stage 2: 60–89
1.13
0.57–2.21
0.7311
Stage 2: 60–89
1.56
0.84–2.89
0.1564
Stage 3a: 45–59
1.73
0.85–3.51
0.1324
Stage 3a: 45–59
2.42
1.26–4.67
0.0083
Stage 3b: 30–44
3.63
1.83–7.18
0.0002
Stage 3b: 30–44
4.29
2.29–8.02
<0.0001
Stage 4: 15–29
4.20
2.10–8.37
<0.0001
Stage 4: 15–29
5.47
2.89–10.35
<0.0001
Stage 5: <15
5.83
2.62–12.98
<0.0001
Stage 5: <15
8.17
3.98–16.78
<0.0001
Adjusted model 2
<0.0001
Adjusted model 2
<0.0001
Stage 1: ≥90
1
Reference
Stage 1: ≥90
1
Reference
Stage 2: 60–89
1.12
0.55–2.28
0.7493
Stage 2: 60–89
1.70
0.88–3.28
0.1139
Stage 3a: 45–59
1.63
0.77–3.43
0.2013
Stage 3a: 45–59
2.32
1.14–4.70
0.0199
Stage 3b: 30–44
3.40
1.64–7.07
0.0010
Stage 3b: 30–44
4.39
2.22–8.67
<0.0001
Stage 4: 15–29
3.60
1.73–7.51
0.0006
Stage 4: 15–29
5.08
2.55–10.13
<0.0001
Stage 5: <15
5.34
2.27–12.55
0.0001
Stage 5: <15
7.79
3.57–17.02
<0.0001
Adjusted model 3
<0.0001
Adjusted model 3
<0.0001
Stage 1: ≥90
1
Reference
Stage 1: ≥90
1
Reference
Stage 2: 60–89
1.09
0.54–2.23
0.8093
Stage 2: 60–89
1.67
0.86–3.23
0.1270
Stage 3a: 45–59
1.49
0.70–3.18
0.2978
Stage 3a: 45–59
2.14
1.04–4.39
0.0379
Stage 3b: 30–44
3.42
1.64–7.12
0.0010
Stage 3b: 30–44
4.43
2.24–8.76
<0.0001
Stage 4: 15–29
3.60
1.72–7.53
0.0007
Stage 4: 15–29
5.14
2.57–10.28
<0.0001
Stage 5: <15
5.39
2.26–12.88
0.0001
Stage 5: <15
8.00
3.62–17.68
<0.0001
Adjusted model 4
<0.0001
Adjusted model 4
<0.0001
Stage 1: ≥90
1
Reference
Stage 1: ≥90
1
Reference
Stage 2: 60–89
1.25
0.56–2.81
0.5848
Stage 2: 60–89
1.90
0.91–3.97
0.0874
Stage 3a: 45–59
1.44
0.60–3.46
0.4159
Stage 3a: 45–59
2.12
0.94–4.75
0.0688
Stage 3b: 30–44
3.22
1.40–7.43
0.0060
Stage 3b: 30–44
4.03
1.88–8.63
0.0003
Stage 4: 15–29
3.22
1.43–7.71
0.0051
Stage 4: 15–29
4.77
2.19–10.37
0.0001
Stage 5: <15
6.71
2.51–17.91
0.0001
Stage 5: <15
9.82
4.05–23.80
<0.0001
CKD: chronic kidney disease; HR: hazard ratio; CI: confidence interval; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease epidemiology collaboration. Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, and duration of diabetes. Model 3: adjusted for age, sex, duration of diabetes, and baseline HbA1c level. Model 4: adjusted for age, sex, duration of diabetes, baseline HbA1c level, and medication for hypertension.
